The Safe Return of Face-to-Face Teaching in the Post-COVID-19 Era at a University in Southern Italy: Surface Monitoring as an Early Warning System DOI Creative Commons
Osvalda De Giglio, Francesco Triggiano, Francesca Apollonio

и другие.

Applied Sciences, Год журнала: 2023, Номер 13(24), С. 13214 - 13214

Опубликована: Дек. 13, 2023

Environmental monitoring for SARS-CoV-2 has become a useful adjunct to clinical testing because it is widely available and relatively inexpensive. During the period May–December 2022 (spring–summer: May–September–autumn: October–December), we assessed presence viability of virus on surfaces in university settings Apulia region (Southern Italy) after resumption face-to-face teaching activities evaluated surface as an early warning system. The sampling plan provided selection 75% types (e.g., student teacher desks, computer, handrail) different materials (plasticized wood, metal, plastic) present environments. Overall, 5.4% (all students’ desks) resulted positive with RT-PCR negative viral culture. Greater contamination was found spring–summer than autumn (χ2 test Yates correction = 7.6003; p-value 0.006). Poisson regression model showed direct association between average number COVID-19 cases among students seven days following percentage swabs day (Intercept 5.32498; β 0.01847; p < 0.001). Our results show that environmental SARS-CoV-2, especially crowded such universities, could be tool warning, even end emergency.

Язык: Английский

Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants DOI Creative Commons
Haonan Yang, Huimin Guo, Aojie Wang

и другие.

Nature Communications, Год журнала: 2024, Номер 15(1)

Опубликована: Сен. 4, 2024

Язык: Английский

Процитировано

14
SARS-CoV-2 neutralizing antibody bebtelovimab – a systematic scoping review and meta-analysis DOI Creative Commons

Mabel Nyit Yi Liew,

Kok Pim Kua, Shaun Wen Huey Lee

и другие.

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Авг. 28, 2023

Introduction The COVID-19 pandemic is a major global public health crisis. More than 2 years into the pandemic, effective therapeutic options remain limited due to rapid viral evolution. Stemming from emergence of multiple variants, several monoclonal antibodies are no longer suitable for clinical use. This scoping review aimed summarize preclinical and evidence bebtelovimab in treating newly emerging SARS-CoV-2 variants. Methods We systematically searched five electronic databases (PubMed, CENTRAL, Embase, Global Health, PsycINFO) date inception September 30, 2022, studies reporting on effect infection, using combination search terms around ―bebtelovimab‖, ―LY-CoV1404‖, ―LY3853113‖, ―coronavirus infection‖. All citations were screened independently by two researchers. Data extracted thematically analyzed based study design adhering stipulated approaches. Results Thirty-nine included, thirty-four non-clinical narratively synthesized, meta-analyzed. revealed not only potently neutralized wide-type existing variants concern such as B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), but also retained appreciable activity against Omicron lineages, including BA.2.75, BA.4, BA.4.6, BA.5. Unlike other antibodies, was able bind epitope S protein exploiting loop mobility or minimizing side-chain interactions. Pooled analysis depicted that rates hospitalization, ICU admission, death similar between therapies. Bebtelovimab associated with low incidence treatment-emergent adverse events. Conclusion Preclinical suggests be potential treatment amidst has comparable efficacy therapies without evident safety concerns.

Язык: Английский

Процитировано

10
Berbamine prevents SARS-CoV-2 entry and transmission DOI Creative Commons

Srikanth Sadhu,

Sandeep Goswami,

Ritika Khatri

и другие.

iScience, Год журнала: 2024, Номер 27(12), С. 111347 - 111347

Опубликована: Ноя. 8, 2024

Язык: Английский

Процитировано

1
Research progress of spike protein mutation of SARS-CoV-2 mutant strain and antibody development DOI Creative Commons

Xinkang Huan,

Jiuyu Zhan,

Hongwei Gao

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Ноя. 18, 2024

The coronavirus disease 2019 (COVID-19) is a respiratory with very high infectious rate caused by the Severe Acute Respiratory Syndrome Coronavirus-2(SARS-CoV-2). Because SARS-CoV-2 easy to mutate, continuous emergence of variant strains not only enhances infectivity but also brings great obstacles treatment COVID-19. Neutralizing antibodies have achieved good results in clinical application novel pneumonia, which can be used for pre-infection protection and patients. This review makes detailed introduction mutation characteristics SARS-CoV-2, focusing on molecular mechanism affecting impact monoclonal antibody therapy, providing scientific reference prevention research development drugs.

Язык: Английский

Процитировано

1
Defining the features and structure of neutralizing antibody targeting the silent face of the SARS‐CoV‐2 spike N‐terminal domain DOI Creative Commons
Zhaoyong Zhang, Yuanyuan Zhang, Yuting Zhang

и другие.

MedComm, Год журнала: 2024, Номер 5(12)

Опубликована: Ноя. 28, 2024

Abstract Research on virus/receptor interactions has uncovered various mechanisms of antibody‐mediated neutralization against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). However, understanding by antibodies targeting the silent face, which recognize epitopes glycan shields, remains limited, and their potential protective efficacy in vivo is not well understood. This study describes a face neutralizing antibody, 3711, targets non‐supersite N‐terminal domain (NTD) spike protein. Cryo‐EM structure determination 3711 Fab complex reveals novel epitope shielded glycans spike's face. Antibody inhibits interaction between receptor‐binding (RBD) human angiotensin‐converting enzyme (hACE2) through steric hindrance exhibits superior effects compared to other reported NTD‐targeted monoclonal (mAbs). Competition assays antibody repertoire analysis indicate rarity 3711‐related SARS‐CoV‐2 convalescents, suggesting infrequency NTD face‐targeted during infection. As first SARS‐CoV‐2, identification mAb with its mechanism, enhances our shields elucidates epitope‐guided viral mutations that evade specific antibodies.

Язык: Английский

Процитировано

0
The Safe Return of Face-to-Face Teaching in the Post-COVID-19 Era at a University in Southern Italy: Surface Monitoring as an Early Warning System DOI Creative Commons
Osvalda De Giglio, Francesco Triggiano, Francesca Apollonio

и другие.

Applied Sciences, Год журнала: 2023, Номер 13(24), С. 13214 - 13214

Опубликована: Дек. 13, 2023

Environmental monitoring for SARS-CoV-2 has become a useful adjunct to clinical testing because it is widely available and relatively inexpensive. During the period May–December 2022 (spring–summer: May–September–autumn: October–December), we assessed presence viability of virus on surfaces in university settings Apulia region (Southern Italy) after resumption face-to-face teaching activities evaluated surface as an early warning system. The sampling plan provided selection 75% types (e.g., student teacher desks, computer, handrail) different materials (plasticized wood, metal, plastic) present environments. Overall, 5.4% (all students’ desks) resulted positive with RT-PCR negative viral culture. Greater contamination was found spring–summer than autumn (χ2 test Yates correction = 7.6003; p-value 0.006). Poisson regression model showed direct association between average number COVID-19 cases among students seven days following percentage swabs day (Intercept 5.32498; β 0.01847; p < 0.001). Our results show that environmental SARS-CoV-2, especially crowded such universities, could be tool warning, even end emergency.

Язык: Английский

Процитировано

0